INIS
liver
75%
diseases
58%
patients
50%
therapy
41%
toxicity
41%
radioembolization
41%
metastases
33%
melanomas
33%
evaluation
16%
solids
16%
tumors
16%
control
16%
refractories
16%
yttrium 90
16%
WHO
16%
cancer
8%
size
8%
skin
8%
safety
8%
lymphocytes
8%
doses
8%
fatigue
8%
nausea
8%
aminotransferases
8%
survival time
8%
vomiting
8%
necrosis
8%
bilirubin
8%
Nursing and Health Professions
Patient
100%
Radioembolization
41%
Combination Therapy
33%
Toxicity
33%
Metastatic Melanoma
33%
Diseases
25%
Disease Control
16%
Solid Malignant Neoplasm
16%
Progression Free Survival
16%
World Health Organization
16%
Evaluation Study
16%
Yttrium 90
16%
Overall Survival
8%
National Health Organization
8%
Kaplan Meier Method
8%
Bilirubin
8%
Nausea
8%
Nomenclature
8%
Survival Time
8%
Systemic Therapy
8%
Fatigue
8%
Electric Potential
8%
Aspartate Aminotransferase
8%
Necrosis
8%
Dose
8%
Medicine and Dentistry
Radioembolization
41%
Toxicity
33%
Combination Therapy
33%
Metastatic Melanoma
33%
Diseases
25%
Liver
25%
Progression Free Survival
16%
Progressive Disease
16%
Yttrium 90
16%
Evaluation Study
16%
Solid Malignant Neoplasm
16%
Therapeutic Procedure
16%
Association
16%
Experience
16%
Bilirubin
8%
Overall Survival
8%
Systemic Therapy
8%
Nausea
8%
Kaplan Meier Method
8%
Necrosis
8%
Survival Time
8%
Aspartate Aminotransferase
8%
Lymphocytotoxicity
8%
Fatigue
8%
Skin
8%
Pharmacology, Toxicology and Pharmaceutical Science
Toxicity
33%
Metastatic Melanoma
33%
Diseases
25%
Progression Free Survival
16%
Yttrium 90
16%
Solid Malignant Neoplasm
16%
Bilirubin
8%
Overall Survival
8%
Nausea
8%
Lymphocytotoxicity
8%
Aspartate Aminotransferase
8%
Survival Time
8%
Necrosis
8%
Fatigue
8%